You are reading 1 of 2 free-access articles allowed for 30 days
The sole applicant for the National Cancer Control Programme’s (NCCP) Clinical Lead for Haemato-oncology has withdrawn from the process, the Medical Independent (MI) has learned.
The issue was discussed at a meeting of the NCCP’s executive management team on 7 October.
The Clinical Lead for Haemato-oncology is a new role intended to formalise the advice provided to the NCCP on haemato-oncology issues. This advice has been provided by a clinician nominated by the Irish Haematology Society.
“An expression of interest for the role was advertised in 2019,” an NCCP spokesperson told MI.
“Unfortunately, this post was not filled as a result of this process and discussions are ongoing in relation to the future filling of this role.”
At the October meeting, it was stated that internal discussion would take place on approaches to recruitment to this post, as well as to the cytogenetics oversight role.
At the previous meeting, on 2 September, it was stated that no expression of interest was returned for the role of National Clinical Lead for Cytogenetics.
An update on hereditary cancer genetics was provided at the September meeting.
The meeting heard how the NCCP was due to meet with the Northern Ireland cancer genetics service to discuss how services are provided in the region.
It also heard how a draft summary report on a hereditary cancer genetic survey had been submitted to the executive committee.
National Advisor for Medical Oncology Prof Maccon Keane observed that the NCCP should hold a position that adult genetics be located in adult cancer centres.
Meanwhile, Ms Fiona Bonas has been appointed Interim National Director of the NCCP, replacing Dr Jerome Coffey.
Dr Coffey was appointed Interim National Director in 2014, before taking the role on a permanent basis.